Sign in Subscribe
Immunoglobulin A

Efficacy and Safety of Telitacicept in IgA Nephropathy Shown in Study

Strategic Insights

— 1 min read

Researchers at Affiliated to Shanghai Jiao Tong University School of Medicine have conducted a study to evaluate the effectiveness and safety of telitacicept in patients with IgA nephropathy (IgAN). The study, which included 33 IgAN patients, found that telitacicept treatment for at least 3 months resulted in a significant reduction in 24-hour urinary protein and improved clinical outcomes. While the study showed promising results, the researchers noted that further studies are needed to confirm the efficacy and safety of telitacicept in IgAN patients.

Key Takeaways:

  • The study included 33 IgAN patients from Xin Hua Hospital affiliated to Shanghai Jiao Tong University School of Medicine.
  • Telitacicept treatment for at least 3 months resulted in a significant reduction in 24-hour urinary protein, decreasing by 63.90% at 3 months.
  • The telitacicept group achieved a complete remission rate of 36.36% and a partial remission rate of 36.36% at 3 months.
  • The study found that serum creatinine and eGFR remained stable throughout the treatment period.
  • The most common adverse reactions were pain, redness, or itching at injection site, without signs of local infection.
  • The study concluded that preliminary clinical trials have provided supportive evidence for the efficacy and safety of telitacicept as a viable treatment option for IgAN.

Statistics:

  • 24-hour urinary protein decreased by 893.29 mg/day (63.90%) in the telitacicept group at 3 months.
  • Complete remission rate of 36.36% and partial remission rate of 36.36% at 3 months in the telitacicept group.
  • Overall remission rates of 72.73% and 77.27% at 6 months in the telitacicept and control groups, respectively.
  • Serum creatinine and eGFR remained stable throughout the study.

Sources:

  • Research: "Effectiveness and safety of telitacicept in IgA nephropathy: a propensity score matching analysis with a 6-month follow-up." BMC Nephrology, 2025,26(1):1-7.
  • Publisher: BMC Nephrology
  • DOI: 10.1186/s12882-025-04468-7
  • Journal article: https://doi-org.sdpl.idm.oclc.org/10.1186/s12882-025-04468-7
  • Contact: Hui Li, Department of Nephrology, Xin Hua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine.

Read more